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Methods for Evaluating Prediction Performance
of Biomarkers and Tests
Margaret Pepe and Holly Janes
1 Introduction
1.1 Background
Predicting an individual’s risk of a bad outcome is a key component of medical deci-
sionmaking. For example, the FraminghamRisk Calculator (www.framinghamheartstudy.org)
provides 10 year risks of cardiovascular event outcomes such as coronary heart dis-
ease and myocardial infarction events as functions of risk factors [5]. Risk factors
for hard coronary heart disease (HCHD), defined as myocardial infarction or coro-
nary death, include age, smoking status, treatment for hypertension and levels of
total cholesterol, high density lipoproteins and systolic blood pressure. If the 10-
year risk exceeds 20%, longterm treatment with cholesterol lowering drug therapy
is recommended. Another risk calculator routinely used in clinical practice is the
Breast Cancer Risk Assessment Tool (BCRAT)[30]. The predicted outcome may
be a future event such as a cardiovascular event for the Framingham Risk Calcu-
lator or breast cancer diagnosis for BCRAT. However, a current condition can also
constitute the predicted outcome. For example, presence of acute kidney injury is
the outcome predicted in Parikh et al. [15] and presence of critical illness requiring
hospitalization is the outcome predicted by Seymour et al. [25]. New molecular bi-
ology techniques for measuring biomarkers and new imaging technologies portend
the availability of excellent predictors of risk in the future. Moreover, easy dissemi-
nation of risk calculators over the internet will increase the impact of risk prediction
models on clinical practice.
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2 Margaret Pepe and Holly Janes
In this chapter we discuss methods for evaluating risk prediction models. Since
the goal is to use risk calculators in medical decision making, our perspective is that
the crucial evaluations are about determining whether or not good decisions can be
made with use of the risk prediction model. For much of the chapter we define a
good decision rule as one that recommends treatment for people who would get the
bad outcome in the absence of treatment (called cases here) and does not recom-
mend treatment for those who would not have a bad outcome (called controls here).
The rationale is that the cases could possibly benefit from treatment while the con-
trols would not benefit but would be subjected to toxicities, expenses and other costs
associated with treatment. Therefore, we consider that a prediction model is good
if it leads to a large proportion of cases being classified into a treatment category
and a large proportion of controls into a no-treatment category. However, prediction
models are not just classifiers. A prediction model is an algorithm that people use
to calculate their risk and as such it has real meaning and interpretation for individ-
uals. This must be accounted for in evaluating a prediction model and sets it apart
from evaluations of other classifiers such as diagnostic tests where a numerical score
itself may not have meaning.
1.2 Notation and Assumptions
We writeD for the outcome of interest and assume that it is binary D= 1 for a case
and D = 0 for a control. If the outcome is an event occurring within a specific time
period, for example a cardiovascular event within 10 years, the cases may be called
events and the controls may be called nonevents. The prevalence or event rate in the
population is denoted by ρ:
ρ = P(D= 1).
The predictors are denoted by X and Y , both of which may be multidimensional. In
Section 2, we consider a single risk model and use X for the predictors in the model.
In Section 3, we consider two nested risk models, one with the baseline predictors
denoted by X and one expanded model that includes the predictors Y in addition to
X .
To focus the presentation we assume that in the absence of predictor informa-
tion subjects do not receive treatment. The purpose of the risk model is to identify
subjects for treatment. One may be interested in the opposite scenario in some set-
tings. That is, standard of practice may be to receive treatment and the purpose of
the model is to identify subjects at low risk who may forego treatment. This setting
can be dealt with using methods analogous to those we describe here and is men-
tioned later, but for the most part, and to keep the discussion focused, we consider
the default no-treatment scenario.
We assume that data are available for a cohort of N independent untreated sub-
jects. We write the data as {(Di,Yi,Xi); i= 1, . . .,N}. Most of this chapter concerns
conceptual formulations of measures to quantify and compare the prediction perfor-
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mance of risk models. As such, sampling variability and statistical inference is not a
major focus, at least in sections 2 and 3. In other words we assume N is very large.
1.3 Illustrative Data
For illustrative purposes we use a simulated data set. The simulated data is available
on the DABS website (http://labs.fhcrc.org/pepe/dabs/index.html) and was previ-
ously used in a publication [18]. It reflects the prevalence and risk ranges that have
been reported for cohort studies of cardiovascular disease. The data are comprised of
10,000 observations of which 1017 are case subjects and 8983 are control subjects.
Predictors X and Y are one-dimensional and continuous. In practice the predictors
X and/orY may be scores derived from multiple risk factors or biomedical measure-
ments. In Section 2 we focus on the predictorX only, while in Section 3 we consider
X and Y together as predictors. Table 1 shows fitted logistic regression models for
these data.
Table 1 Estimated coefficients for baseline and enhanced risk models.
BaselineModel EnhancedModel
Factor Coefficient SE Coefficient SE
Intercept -3.67 0.07 -4.23 0.09
X 1.72 0.05 1.77 0.05
Y 1.01 0.05
1.4 Chapter Outline
In section 2 we discuss the concept of risk and validity of a risk model. The perfor-
mance of a riskmodel is discussed in Section 3. A plethora of performance measures
are used to assess prediction performance and we describe the main ones. Insights
and relationships amongst the measures are provided. In section 4 we consider the
comparison of two risk prediction models focusing especially on the comparison of
two nested models. This is a somewhat controversial area of statistical methodology
where public debate and discourse is needed. We hope that this chapter will add
constructively to the discourse.
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2 Validity of the Risk Calculator
2.1 What is risk(X)?
The function risk(x) = P(D = 1|X = x) is the frequency of events among subjects
with predictor values X = x. It is important to remember that statistical analysis de-
livers information about population level entities, such as averages and frequencies
and distributions.We emphasize this point because the term ‘individual level risk’ is
often used in this era of ‘personalized medicine’. But the risk value calculated from
the risk calculator for subject j with predictors X j, risk(X j), is not the probability of
a random event for that subject. Rather it is the frequency of events in the group of
subjects with the same predictors as him.
To make the distinction concrete, suppose that risk(X j) = 0.20 and consider the
(large) group of subjects with predictors X j. The following scenarios are all consis-
tent with risk(X j) = 0.20: (i) 20% of the subjects are destined to have the event with
probability 1 while 80% are destined not to have the event; (ii) for each subject i
there is a stochastic mechanism giving rise to an event D = 1 with individual level
probabilitypii = 0.20; (iii) 10% of subjects are destined to have the event (pii = 1.00
for them), 50% are destined not to have the event (pii = 0.00 for them) and for 40%
of subjects the outcome is stochastic with pii = 0.25. Gail and Pfeiffer [6] discuss
the distinction between the unobservable individual level probabilities denoted by
pii and risk(x) = P(D= 1|X = x). They note the equality: risk(x) = E{pii|Xi = x}. A
simulated example that illustrates the distinction can be found in Pepe [18].
Unless repeated observations of the outcomewere available for an individual,one
cannot make inference about individual level risks. In this sense, the individual level
risks, i.e. the pii’s, are not observable. It is not clear that they are even well defined
when a subject can only experience one event. We regard the concept of individual
level risk pi as a useless distraction. Individualized risk will not be discussed further
in this chapter.
Risk is a function of the predictors modeled. It is important to remember that an
individual with two sets of predictors Xi and Yi can have at least three risk values,
risk(Xi) = P(D = 1|X = Xi), risk(Yi) = P(D = 1|Y = Yi) and risk(Xi,Yi) = P(D =
1|X = Xi,Y =Yi). Each is his ‘true risk’. Each is a frequency of events but calculated
amongst different groups of subjects: those with X = Xi, those withY =Yi and those
with X = Xi and Y =Yi, respectively.
2.2 The Meaning of Calibration
The traditional definition of calibration is that a well calibrated risk calculator
risk∗(·), is one for which the frequency of events among subjects with X = x is
equal to risk∗(x) : P(D= 1|X = x) = risk∗(x). When X is multidimensional it can be
difficult to assess calibration defined in this strong sense. A weaker definition of cal-
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ibration is typically used in practice: the criterion is that P(D= 1|risk∗(X) = r)≈ r
for all r. In words, if the frequency of events is r among subjects whose calculated
risks are equal to r, then the model risk∗( ) is considered well calibrated in the
weak sense. This level of validity seems like a minimal requirement to justify use of
the risk model in practice.
We note that strong calibration implies weak calibration because under strong
calibration, where P(D = 1|X = x) = risk∗(x) we have P(D = 1|risk∗(X) = r) =
E{P(D= 1|X = x)|risk∗(X) = r}= E{risk∗(X)|risk∗(X) = r}= r. However, weak
calibration does not imply strong calibration and must not be interpreted as such.
Calibration is an attribute that may not transport from one population to another.
For example, if there are predictors (known or unknown) that are not included in the
model and that have different distributions in two populations, the true risk models
in the two populations will likely be different, P(D = 1|X , population A) 6= P(D =
1|X , population B). Strong calibration may not transport for this reason. However,
if all relevant predictors are included in the model, strong calibration will not be
affected by a change in the distribution of predictors. On the other hand, a model
that is weakly calibrated but not strongly calibrated may not transport its weak cali-
bration to other populations where distributions of modeled covariates differ.
2.3 Assessing Calibration
To evaluate calibration one compares the observed event rates within subgroups
of subjects defined by the modeled predictors to the average modeled risk values
among those subjects. The subgroups are usually selected as having modeled risk
values in a narrow range. A visual aid to this comparison is the predictiveness curve
event rate (0.1017)
0.0
0.2
0.4
0.6
0.8
1.0
Risk
0 20 40 60 80 100
Risk percentile
Fig. 1 Visual assessment of calibrationwith the predictiveness curve.
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[20]. The plot orders subjects from lowest to highest modeled risk, plotting the risk
versus the corresponding percentile. The x-axis, allows one to identify subgroups
similar in regards to modeled risk. For example, groups may be defined by decile of
modeled risk. The observed event rate in each subgroup is superimposed on the plot
as shown in Figure 1. If the circles follow the predictiveness curve, we conclude
that modeled risks are close to observed risks and the model is well calibrated (in
the weak sense) in the dataset. The predictiveness curve in Figure 1 shows that the
fitted model is extremely well calibrated. An alternative but related visual display
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Fig. 2 Calibration with the calibration plot.
is the calibration plot (Figure 2) [25]. This also uses intervals of modeled risk (e.g.
deciles) but plots observed event rates versus average modeled risk producing points
that should lie along the 45◦ line if the model is well calibrated. A disadvantage
of the calibration plot versus the predictiveness curve is that points can be more
clumped. Moreover the variability in modeled risk within an interval risk category
is not evident from the calibration plot. If substantial variation exists in a category
onemight choose to use smaller subdivisions of that category in comparing observed
event rates with modeled rates.
The Hosmer-Lemeshow test is often reported as a test for calibration [14]. It also
uses subsets defined by modeled risk, typically deciles, and calculates
H ≡
10
∑
k=1
Nk
(0k− rˆk(X))
2
rˆk(X)(1− rˆk(X))
where Nk = the number of subjects in the k
th category, 0k = the observed event rate
and rˆk(X) is the average estimated modeled risk. Under the null hypothesis of good
model calibration, the statistic H has a chi-squared distribution. The statistic corre-
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sponds closely with the predictiveness and calibration plots in that it compares 0k
and rˆk. However, the statistic has been criticized for many reasons including that it
is highly dependent on sample size (almost certainly significant if N is large enough
and non-significant if N is small enough). In of itself, it does not convey the extent
to which the model is well calibrated to the data. But it can serve as a descriptive
adjunct to the visual display of calibration manifested in the predictiveness or cali-
bration plots. Although deciles of risk are typically used for the predictiveness plot,
calibration plot and Hosmer-Lemeshow statistic, as mentioned above there is no
reason that other subgroupings couldn’t be used.
2.4 Achieving a Well Calibrated Model
This chapter does not cover procedures to fit regression models. We refer to text-
books that cover the topic in depth [8, 26]. When only a few predictors are included,
the task of fitting a model that is well calibrated to the data and not over-fit is rel-
atively straightforward. Although sampling variability in the fitted model remains,
assuming good study design practices have been followed and in the absence of ad-
ditional data, one will propose the fitted model for use in practice. The next task will
be to evaluate its performance for prediction.
Sometimes an externally fitted model will be proposed for validation on a new
dataset. If the model is not found to be well calibrated on the new dataset, it must be
regarded as not having been validated. Nevertheless, some investigators proceed to
evaluate its classification performance. In our opinion this is inappropriate. Individ-
uals will want to use the prediction model not just as an aid in classification but to
calculate their risk as a function of predictors. A poorly calibrated model is known
to be invalid for this purpose and should be abandoned.
A better strategy perhaps is to derive a revised risk prediction model with the
new dataset. This may be done by using the original modeled risk value as a sole
predictor and fitting a model with that single predictor to the data. This is called
recalibration. Because only one predictor is involved it should be easy to arrive at
a revised model that is well calibrated to the new dataset and therefore worthy of
evaluation for its predictive performance.
Another strategy is to begin anew and fit a model with each predictor in the
original model included as a candidate predictor for the new model. If many pre-
dictors are involved, issues pertaining to overfitting arise and one will need to use
techniques such as ‘shrinkage’ in order to arrive at a believable model. Fruitfully
applying such techniques requires considerable skill and experience. An advantage
of starting over with the new dataset is that a combination of predictors that is closer
to optimal for application in the target population may be arrived at. Recalibrating
an existing model is easer and subject to less sampling variability, but one maintains
the same predictor combination of the original model that may be suboptimal if it
was derived from a population that is not the one of interest.
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Why might an externally derived model fail to be well calibrated? Certainly if
it was derived in a different population with different predictor effects (or distribu-
tions, see 2.2) it may not be valid for use in the target population. Another common
cause is overfitting the model in the original population.
For the remainder of this chapter we assume that a model that is well calibrated
is to be evaluated for its performance.
3 Measuring Prediction Performance of a Single Model
3.1 Context
The focus of this section is on describing conceptual approaches to evaluating a
risk prediction model. We suppose that we have an extremely large population and
the true risk function, risk(X) = P(D = 1|X), is available. How do we measure the
performance of this risk function for use in the population?
It is important to remember that the purpose of calculating risk(X) is to af-
fect medical decisions. Recall that we assume that in the absence of knowledge of
risk(X) no treatment will be offered, but that if risk(X) is found to be large enough,
treatment will be offered. Implicitly we assume that treatment must have associated
with it some costs, e.g. toxicity, monetary costs, inconvenience. Otherwise all sub-
jects, regardless of their risk value, could be treated even if the benefit was minimal.
3.2 Case and Control Risk Distributions
All metrics to gauge the performance of a risk model are derived from the distribu-
tion of risk(X) in cases and in controls. Having a visual display of the distributions
is often helpful. Although probability density functions (Figure 3) give a sense for
the separation between case and control distributions, cumulative distributions, or
1− cd f s denoted by HRD and HRD¯ in Figure 4 are more useful because they ex-
plicitly show the proportions of cases and controls above any threshold value used
to define ‘high risk.’ Since decisions to opt for treatment will be based on ‘high risk’
designation, it is of interest and can be seen directly from the cdfs how many cases
and controls are recommended for treatment using the risk model.
Gail and Pfeiffer [6] make the point that the cumulative distribution function(cdf)
of risk in the population as a whole, cases and controls together, is sufficient to
calculate performance measures. This is true because the case distribution and the
control distribution can both be calculated from the overall population distribution
of risk. Using f (risk(X) = r) to denote probability density for risk(X) at r, this
follows because
http://biostats.bepress.com/uwbiostat/paper384
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threshold = t
risk
cases
controls
Fig. 3 Case and Control risk distributions on the logit scale.
f (risk(X) = r|D= 1) =
P(D = 1|risk(X) = r)
P(D= 1)
f (risk(X) = r)
=
r f (risk(X) = r)
P(D = 1)
f (risk(X) = r|D= 0) =
(1− r) f (risk(X) = r)
P(D = 0)
The overall cdf of risk(X) in the population as a whole is shown by the predictive-
ness curve that displays quantiles of risk in the population (Figure 5) but we find the
case and control specific cdfs to be a more informative display.
The receiver operating characteristic (ROC) curve, that plots HRD(r)=P(risk(X)>
r|D= 1) versus HRD¯(r) ≡ P(risk(X) > r|D = 0) (Figure 6) is another popular vi-
sual display to assess performance. When the case and control distributions are well
separated, the ROC curve
ROC( f ) =HRD(HR
−1
D¯
( f ))
lies close to the upper left hand corner of the [0,1]× [0,1] quadrant. Huang and
Pepe [10]show that the ROC curve and prevalence, ρ = P[D = 1], together can
be used to calculate the predictiveness curve. And, since the predictiveness curve
can be used to calculate the case and control distributions of risk it follows that
(ROC( f ), f ∈ (0,1) ; ρ) contain all the information available in the case and control
distributions of risk(X). However, the risk thresholds r corresponding to the points
on the ROC curve, (HRD¯(r),HRD(r)), are not visible from the ROC curve detracting
from its interpretation. When plotting a single ROC curve it is possible to add the
risk thresholds to the axes (Figure 6). However, with two or more ROC curves this
is not possible. Since ROC curves do not align models according to the same risk
Hosted by The Berkeley Electronic Press
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0
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Risk threshold = r
HRD(r)
HRD(r)
Fig. 4 Case and control distributions of risk shown with 1−cd f functions,HRC(t) = P(risk(X)>
t|D= 1) and HRN(t) = P(risk(X)> t|D= 0)
thresholds and do not display risk thresholds they are less useful for evaluating
predictionmodels than they are for evaluating diagnostic tests whose numeric scales
are often irrelevant in data displays.
3.3 Risk thresholds
How should one choose the risk threshold for designating a patient as at sufficiently
high risk to warrant treatment? Intuitively the costs and benefits associated with
treatment dictate the choice. If the treatment is very costly in terms of toxicities,
monetary expense or inconvenience, a high threshold may be warranted. If the treat-
ment is very likely to be effective at preventing a bad outcome, this might lower the
threshold for treatment. In the extreme, an ineffective or prohibitively costly treat-
ment dictates use of a risk threshold close to 1 corresponding to few people being
treated. At the other extreme, a highly effective inexpensive treatment with few tox-
icities dictates that many people should be treated, i.e., use of a low risk threshold.
An explicit relationship is given in the next result between the risk threshold for
treatment, rH , and the net costs and benefits of treatment. Write the net benefit of
treatment to a subject who would have an event in the absence of treatment as B. For
example, if treatment reduces the risk of an event by 50%, the benefit might be 0.5×
http://biostats.bepress.com/uwbiostat/paper384
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event rate (0.1017)
0.0
0.2
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0.8
1.0
Risk
0 20 40 60 80 100
Risk percentile
Fig. 5 The predictiveness curve that shows the quantiles of risk(X) in the population. The predic-
tion curve for the ideal model where all cases have risk= 1 and all controls have risk= 0, is shown
as a dashed step function.
_
1
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FPR = HRD(r)
Fig. 6 ROC plot with risk thresholds r shown on top and right axes.
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{value of an event} and the net benefit is the benefit less the costs associated with
treatment for a subject who would otherwise have an event. Note that these costs
must be put on the same scale as the benefit, i.e. {value of an event} in our example.
A subject who would not have an event in the absence of treatment suffers only costs
and no benefit from being treated. We use Cost to denote the corresponding cost for
such a subject.
Result 1
The risk threshold for treatment that should be employed to ensure subjects with
risk values risk(X) benefit on average is
rH = Cost/(Cost+B).
The threshold does not depend on the model or on the predictors in the model.
Proof. The expected net benefit for subjects with risk(X) = r is
B P(D = 1|risk(X) = r)−Cost P(D= 0|risk(X) = r) = B r −Cost(1− r)
which is positive if
r
1− r
>
Cost
B
In other words, to ensure a positive average benefit for subjects with risk values r
they should opt for treatment if r/(1−r)>Cost/B and should not opt for treatment
if r/(1− r)< Cost/B. That is the treatment risk threshold is Cost/(Cost+B). uunionsq
The result agrees with the intuition that high costs and/or low benefits should be
correspond to high values of the risk threshold for opting for treatment.
Example Suppose treatment reduces the risk of breast cancer within 5 years
by 50% but it can cause other bad outcomes such as other cancers, cardiovas-
cular events and hip fractures that are considered equally bad. Assume other
bad outcomes, O, occur with a frequency of x in the absence of treatment
but with a frequency of z in the presence of treatment regardless of whether
D = 1 or 0. Let D(0),D(1),O(0),O(1) denote the potential outcomes with
and without treatment. A subject who would not develop breast cancer absent
treatment suffers the increased risk of other bad events; his/her net cost of
treatment is
P(D = 1 or O= 1|T = 1,D(0) = 0)−P(D= 1 or O= 1|T = 0,D(0) = 0)
= P(O = 1|T = 1,D(0) = 0)−P(O= 1|T = 0,D(0) = 0)
= P(O = 1|T = 1)−P(O = 1|T = 0) = z− x.
The net benefit of treating a subject who would get breast cancer absent treat-
ment is the reduction in his/her event probability,
http://biostats.bepress.com/uwbiostat/paper384
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P(D= 1 or O= 1|T = 0,D(0) = 1)−P(D= 1 or O= 1|T = 1,D(0) = 1)
= 1− [P(D= 1|T = 0,D(0) = 1)+P(D = 0 and O = 1|T = 1,D(0) = 1)]
= 1− [0.5+(1−0.5)P(O= 1|T = 1)] = 0.5+0.5z
The treatment risk threshold is therefore z−x
z−x+0.5(1+z) .
In practice it is often difficult to specify costs and benefits associated with treat-
ment. It can be especially difficult to specify them on a common scale when they
are qualitatively different entities. On the other hand a treatment threshold for risk
is often easier to specify. For example, the ATP guidelines recommend that sub-
jects with risks above 20% consider longterm treatment with cholesterol lowering
therapy to reduce risk of cardiovascular events. Individuals make decisions such as
whether or not to have genetic testing of their fetus based on their risk of having a
child with genetic abnormalities. Their chosen risk threshold is often derived intu-
itively from their knowledge of the qualitative costs and benefits of amniocentesis.
We similarly make decisions about procuring insurance using our tolerance for risk.
Result 1 tells us the explicit relationship between the risk threshold and the per-
ceived cost-benefit ratio. For example, by choosing a risk threshold equal to 20%
for cholesterol lowering therapy, we are implicitly stating that the net benefit of
therapy for a would-be case is 4 times the net cost of therapy for a would-be control
because
rH
1−rH
= .2/(1− .2)= 1/4.
3.4 Summary Statistics When a Risk Threshold is Available
In this section we consider settings where a risk threshold, rH , exists that defines
high risk status with possible recommendation for treatments or, perhaps, for entry
into a clinical trial. The context then is essentially reduced to a binary classification
rule, high risk or not high risk, and measures commonly used to summarize perfor-
mance of binary classifiers are appropriate. We already defined the proportions of
cases and controls classified as high risk as
HRD(rH) = P(risk(X) > rH |D= 1)
HRD¯(rH) = P(risk(X) > rH |D= 0).
A perfect model classifies all cases and no controls as high risk, HRD(rH) = 1
and HRD¯(rH) = 0. A good model classifies a large proportion of cases as high risk
and a low proportion of controls as high risk. Terms commonly used for HRD(rH)
are true positive rate and sensitivity while false positive rate and 1-specificity are
terms used for HRD¯(rH).
The HRD(rH) is a good attribute of a prediction model while HRD¯(rH) is a neg-
ative attribute. The expected population net benefit of using the model with risk
threshold rH , NB(rH), combines the two into an overall population measure that
balances the positive and negative attributes:
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NB(rH) = P(risk(X) > rH){BP(D = 1|risk(X) > rH)−Cost P(D = 0|risk(X)> rH)}
= B P(risk(X) > rH |D= 1)P(D = 1)−Cost P(risk(X) > rH |D= 0) P(D = 0)
= BHRD(rH)ρ−CostHRD¯(rH)(1−ρ).
_
0
1
0 ρ=.1017 .2 .4 .6 .8 1
Risk threshold = r
HRD(r)
HRD(r)
0
1
sNB(r)
0 ρ=.1017 .2 .4 .6 .8 1
Risk threshold = r
Fig. 7 Proprtions of cases and controls above risk threshold r and corresponding standardized net
benefit.
Observe that NB(rH) is an expectation over the entire population and assumes treat-
ment is offered if risk(X) > rH . In contrast the expected net benefit in the proof of
result 1 concerns only subjects with risk(X) = r and considers their net benefit if
they receive treatment.
Recall that Result 1 tells us that use of the risk threshold rH implies Cost/B =
rH/(1− rH). Substituting into the above gives us an expression for expected net
benefit that depends only on model performance parameters (HRD(rH),HRD¯(rH))
and the constants (ρ, rH).
NB(rH) = {ρHRD(rH)−
rH
1− rH
(1−ρ)HRD¯(rH)}B
Vickers and Elkin [27] propose measuring net benefit in units that assign B a value
1. In those units NB(rH) = ρHRD(rH)−
rH
1−rH
(1−ρ)HRD¯(rH)
A standardized version of NB(rH) is found by dividingNB(rH) by the maximum
possible value that can be achieved, namely ρB, corresponding to a perfect model
with HRD(rH) = 1 and HRD¯(rH) = 0. Baker et al. used the term ‘relative utility’ but
we prefer the more descriptive term standardized net benefit’ and use notation that
corresponds:
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sNB(rH) = NB(rH)/max(NB(rH)) =NB(rH)/ρB
= HRD(rH)−
rH
(1− rH)
(1−ρ)
ρ
HRD¯(rH).
An advantage of standardizing net benefit is that it no longer depends on the
measurement unit B, an entity that is sometimes difficult to digest. sNB(rH) is a
unitless numerical summary in the range (0,1).
Another interpretation for sNB(rH) is that it discounts the true positive rate
HRD(rH) using the scaled false positive rate HRD¯(t) to yield a discounted true pos-
itive rate. The FPR is scaled so that the units are on the same scale as the TPR.
sNB(rH) can therefore be interpreted as the true positive rate of a prediction model
that has no false positives but equal benefit.
16.7 %
risk
cases
controls
0
.70
1
TPR
0 0.115 1
FPR
Fig. 8 ROC−1(0.7)−0.115
In our opinion a reasonably complete reporting of a prediction model’s perfor-
mance is given by HRD(rH), HRD¯(rH) and sNB(rH). One also needs to keep in
mind the prevalence, ρ , and the risk threshold, rH , in order to interpret sNB(rH) and
its components (HRD(rH), HRD¯(rH)).
Example
Figure 7 shows HRD(rH), HRD¯(rH) and their weighted average sNB(rH) for var-
ious choices of risk threshold, rH . For example, at rH = 0.2 we have that 65.2% of
cases and 8.9% of controls are classified as high risk. This corresponds to a ben-
efit that is 45.6% of the maximum possible benefit, where the maximum possible
benefit would be achieved by classifying all 10.17% cases and no controls as high
risk. Alternatively we can consider that the observed true positive rate of 65.2% is
discounted to 45.6% by the 8.9% of controls that are designated as high risk.
The plot in Figure 7 allows one to view performance achieved with different
choices of risk threshold. Observe that the net benefit curve is plotted only for rH >
ρ . This is because the assumed default action is to not treat subjects. In the absence
of predictors, all subjects are assigned risk values ρ . Therefore a risk value of ρ must
correspond to the ‘no treatment’ rule. To be consistent and rational we still assign
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no treatment if risk(X)< ρ when predictors are available. Therefore risk thresholds
for treatment below ρ are not relevant. If one were to instead assign treatment as
the default decision and use the model for decisions to forego treatment, then the
expected net benefit and its standardized version would be calculated differently:
sNB(rL) = (1−HRD¯(rL))−
ρ
(1−ρ)
(1−rL)
rL
(1−HRD(rL)), where rL is the low risk
threshold below which subjects would not receive treatment. Moreover this version
of sNB(rL) would only be calculated for rL < ρ . See Baker [1] for details.
In many circumstances a fixed risk threshold for assigning treatment does not
exist. It can be useful to consider a variety of thresholds. Consider that a predic-
tion model is often developed to determine eligibility criteria for a clinical trial of
a new treatment. For example, new treatments for acute kidney injury are under
development and prediction models are sought to identify high risk subjects for up-
coming clinical trials. Potentially toxic or expensive treatments will require higher
risk thresholds than less toxic, inexpensive treatments. Having displays that show
performance across a range of risk thresholds will allow researchers to entertain use
of risk prediction models for designing trials of different types of treatment.
Another important reason to display performance as a function of risk threshold
is that it allows individuals with different tolerances to assess the value of ascer-
taining predictor information for them. If the distribution of risk thresholds among
individuals in the populationwere known, those could be overlaid on the plots. One
could summarize the information by integrating over the distribution of risk thresh-
olds: HRD¯ = E(HRD¯(rH)) = the overall proportions of controls that do not receive
treatment; HRD = E(HRD(rH)) = the overall proportion of cases who receive treat-
ment; and E(NB(rH)) = expected net benefit.
Although we emphasize HRD(rH), HRD¯(rH) and sNB(rH) as the key measures
of prediction performance for settings where a risk threshold reduces the model to a
binary decision rule, we acknowledge that othermeasures of performance for binary
classifiers could also be reported. Classic measures include: the misclassification
rate, (1−HRD(rH))ρ +HRD¯(rH)(1−ρ); Youden’s index, HRD(rH)−HRD¯(rH);
and the Brier score, E(D− risk(X))2. These measures, like sNB(rH), are functions
of HRD(rH) and HRD¯(rH) but seem to lack its compelling interpretation and prac-
tical relevance. Therefore we do not endorse them for evaluating risk prediction
models.
3.5 Multiple Risk Categories
For prevention of cardiovascular events two possible treatment strategies are rec-
ommended. Longterm treatment with cholesterol lowering drugs is recommended
for high risk subjects while an inexpensive, non-toxic intervention, namely healthy
lifestyle changes, is recommended for subjects at moderately elevated risk. Three
risk categories are therefore of interest in this clinical setting: low risk (risk≤ 5%),
moderate risk (5− 20%) and high risk (≥ 20%). The parameters HRD and HRD¯
are easily generalized to the setting of multiple risk categories. One reports the pro-
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portions of cases in each category and the proportions of controls in each category.
These fractions can be read off of the distribution function displays in Figure 7.
Values are shown in Table 2.
Table 2 Proportions of subjects in each of 3 risk categories. Risk refers to 10-year probability of
a cardiovascular event.
Risk Category Cases Controls
low (< 10%) .112 .657
medium (10−20%) .236 .253
high (> 20%) .652 .089
The standardized net benefit function can also be generalized to accommodate
more than two categories of risk, but it requires specifying some relative costs and
benefits explicitly in addition to the cost-benefit ratios that are implied by the risk
threshold values that define the risk categories.
As an example, suppose there are 3 categories of risk with treatment recommen-
dations being none for the low risk category (risk ≤ rlow), intermediate treatment
for the medium risk category (rlow ≤ risk< rhigh) and intense treatment for the high
risk category (risk > rhigh). Suppose that in the absence of a predictive model all
subjects are recommended for intermediate treatment. We use the following nota-
tion for costs and benefits: Bhigh= net benefit of intense treatment to a subject who
would be a case;Chigh= net cost of intense treatment to a would-be control;Blow= net
benefit of no treatment to a would be control andClow = net cost of no treatment to a
would-be case. All of these quantities are relative to the intermediate treatment and
as always, cases (controls) are those who would (would not) get the bad outcome in
the absence of treatment. The expected net benefit in the population associated with
use of the risk model is:
ρ{−ClowLRD+BhighHRD}+(1−ρ){BlowLRD¯−ChighHRD¯}
where LR and HR are probabilities of being in the low and high risk categories and
the subscripts D and D¯ indicate cases and controls as usual. Let rL and rH denote
the risk thresholds that separate low from medium risk and medium from high risk,
respectively. The arguments of Result 1 implies that (rL/1− rL) = Blow/Clow and
(rH/1− rH) = Chigh/Bhigh. Let λ = Bhigh/Clow be the ratio of the net benefit of
intense treatment to the net cost of no treatment for a subject that would be a case.
The population net benefit of using the model with these risk categories can then be
written as
Bhigh
{
ρ{−
1
λ
LRD+HRD}+(1−ρ){
rL
(1− rL)λ
LRD¯−
rH
1− rH
HRD¯
}
.
This can be standardized by the maximum possible benefit that is achieved with
a perfect predictionmodel, Bhigh{ρ+(1−ρ)
rL
(1−rL)λ
}, yielding the standardized net
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benefit function
sNB(rM, rH) =
ρ{HRD−LRD/λ}+(1−ρ){
rL
(1−rL)λ
LRD¯−
rH
(1−rH )
HRD¯}
ρ+(1−ρ) rL(1−rL)λ
This expression is a function of the risk thresholds, prevalence and case and con-
trol risk distributions and it requires specifying another parameter, namely λ . If we
assume the net benefit of cholesterol lowering treatment relative to healthy lifestyle
is 10 times as large as the net cost of no treatment relative to healthy lifestyle in-
tervention to a would-be case, then the standardized net benefit associated with the
fitted model risk(X) is
0.1017{0.652−0.112/10}−0.8983{0.05
0.95
0.657
10
− 0.20
0.80 ×0.089}
0.1017+0.8983× 0.05
0.95×10
= 77.1%
This example demonstrates that calculation of net benefit associated with a risk
model becomes quite complicated with 3 treatment categories compared with the
calculation when only two treatment categories exist.
3.6 Implicit Use of Risk thresholds
In some circumstances a risk threshold for treatment that maximizes expected ben-
efit cannot be adopted. Policy makers may require that alternative criteria are met.
For example, Pfeiffer and Gail [23] consider using a risk threshold that determines a
proportionv of the population is recommended for treatment: Allocation of financial
resources might determine such a policy. The risk threshold is written as
rH(v) : v= P(risk(X) > rH(v)).
Having fixed v, they propose the proportion of cases that meet the treatment thresh-
old as a measure of model performance:
PCF(v) = P(risk(X) > rH(v)|D= 1),
with larger values indicating better performance. Observe that in our previous nota-
tion we can write
PCF(v) = HRD(rH(v)).
Another policy based criterion might require that a fixed proportion of the cases
are recommended for treatment. In this case the treatment threshold is
rH(w) : w= P(risk(X) > rH(w)|D= 1)
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and the prediction model performance measure proposed by Pfeiffer and Gail is the
corresponding proportion of the population needed to follow, i.e., testing positive,
PNF(w) = P(risk(X)> rH(w)).
Smaller values of PNF(w) are more desirable.
These measures are closely related to the ROC curve that plots the true pos-
itive rate ROC( f ) = P(risk(X) > rH |D = 1) versus the false positive rate f =
P(risk(X)> rH |D= 0) for all possible thresholds rH ∈ (0,1). In fact a little algebra
shows that
PNF(w) = ρw+(1−ρ)ROC−1(w)
and
PCF(v) = ROC( f (v))
where f (v) is found by solving v= ρROC( f )+(1−ρ) f .
One can also directly use ROC curve points to characterize performance and it
follows from arguments above that this approach is essentially equivalent to Pfeiffer
and Gail’s approach. In ROC analysis one fixes the proportion of cases deemed at
high risk, derives the corresponding threshold rH(w) defined above, and evaluates
the corresponding proportion of controls classified as high risk,
ROC−1(w) = P(risk(X)> rH(w)|D= 0).
Alternatively, one can fix the proportion of controls classified as high risk at f ,
derive the corresponding threshold
rH( f ) : f = P(risk(X) > rH( f )|D= 0)
and use as the performance measure the corresponding proportion of cases classified
as high risk
ROC( f ) = P(risk(X) > rH( f )|D= 1).
Example
Using our dataset, suppose we require that w = 70% of cases go forward for
treatment. We calculate that the corresponding risk threshold will be rH(w) = 0.167
and that 11.5% of controls will exceed this threshold with use of the model. See
Figure 8. Since the prevalence is 10.17%, the overall proportion of the population
that will undergo treatment is 17.5%. Using our notation:
w= 70%, rH(w) = 0.167, ROC
−1(w) = .115, PNF(w) = .175
3.7 Measures Independent of Risk Thresholds
When a risk threshold for decision making is not forthcoming, a descriptive sum-
mary of the risk distributions in cases and controls may be of interest. In particular,
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one can describe the separation between the case and control distributions of risk.
For example, we could report: the average risk in cases, 0.391 in our example; the
average risk in controls, 0.069 in our example, and the difference that we write as
MRD, the mean risk difference:
MRD= E(risk(X)|D= 1)−E(risk(X)|D= 0)
which is 0.322 in our example.
The MRD statistic is also called Yates’ slope. It is closely related to the integrated
discrimination improvement (IDI) statistic proposed by Pencina et al. [16] for com-
paring nested risk prediction models. Specifically, if we consider the baseline model
as the null model without predictors, so all subjects have estimated risk equal to ρ ,
then the IDI for comparing the model, risk(X), with the null model is the MRD.
It has also been shown [19] that the MRD can be interpreted as the proportion of
explained variation or coefficient of determination, R2 = var{E(D|X)}/var(D).
Another way to summarize the distance between the case and control risk distri-
butions is with the above average risk difference, AARD:
AARD≡ P(risk(X)> ρ|D= 1)−P(risk(X) > ρ|D= 0).
Noting that the average risk in the population is ρ , this measure compares the pro-
portion of cases with risks exceeding ρ , HRD(ρ) = 0.797 in our example, with the
corresponding proportion of controls, HRD¯(ρ) = 0.198, in our example, and calcu-
lates the difference, AARD= 0.797−0.198= 0.599.
The AARD has several additional noteworthy interpretations. First, Youden’s in-
dex for a dichotomous diagnostic test is defined as the true positive rate minus the
false positive rate. We see that AARD is Youden’s index for the rule that classi-
fies subjects as positive when risk(X) > ρ . Second, we see that AARD= sNB(ρ),
the standardized net benefit defined earlier, for the decision rule that uses ρ as the
high risk threshold. Third, the AARD is closely related to the net reclassification
index (NRI) that will be defined in Section 4.3.2. The NRI is currently a very pop-
ular measure for comparing nested models. It can be shown that for comparing the
model with predictors X , risk(X), to the null model that assigns all subjects a risk
of ρ , AARD= NRI(> 0) and AARD = NRI(ρ) where NRI(> 0) is known as the
continuous NRI and NRI(ρ) is the categorical NRI with two risk categories defined
by the risk threshold ρ .
Interestingly, it can be shown that the difference, HRD(r)−HRD¯(r), is maxi-
mized at r = ρ (see proof of Theorem A.1 [22]). Therefore, the AARD can also
be interpreted as a Kolmogorov-Smirnov distance between the case and control risk
distributions. Finally, Huang and Pepe [10] and Gu and Pepe [7] showed that the
standardized total gain statistic proposed by Bura and Gastwirth [2] as a measure of
predictive capacity of a model risk(X), sTG =
∫
|risk(X)−ρ|dF(X)/2ρ(1−ρ) is
equal to the AARD.
Another nonparametric measure of distance between the case and control risk
distributions is the area under the ROC curve (AUC):
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AUC= P(risk(Xi) ≥ risk(X j)|Di = 1,D j = 0)
where Xi and X j are predictors for randomly drawn independent subjects from the
case and control distributions, respectively. This is also known as theMann-Whitney
U-statistic and is calculated as AUC= 0.884 for our data. The AUC has a long his-
tory of use in evaluating diagnostic tests and other classifiers including risk models.
It is still the most popular metric in use. However, its use in evaluating risk models
has been criticized [3, 21]. One of the criticisms leveled against the AUC is that
the measure has no practical relevance. Certainly this is true. If subjects were pre-
sented in case-control pairs to the physician for deciphering which one is the case,
the measure P(risk(Xi) > risk(X j)|Di = 1,D j = 0) would be of interest. But this is
not the usual clinical task. Another criticism of the AUC is that the measure may be
dominated by differences in risk distributions that are clinically irrelevant. In partic-
ular in a low prevalence or incidence setting, the AUC is dominated by the low end
of the risk range where most of the population’s risks lie. Yet small differences in
the distributions over that range are of no clinical relevance. Consequently the AUC
may not be sensitive to differences in risk distributions over more clinically relevant
ranges.
These two criticisms, practical irrelevance and insensitivity to clinically impor-
tant differences in distributions, however, apply not only to the AUC, but also apply
to other measures of distance between case and control risk distributions such as the
MRD and AARD. We see no particular advantage to MRD or AARD or the related
reclassification measures (IDI and NRI) that will be described later. We caution
against using any of these measures as a sole focus for evaluating and comparing
models. Rather they may be more suitable to assessing if a model is at one extreme
or the other in terms of prediction performance. As such, their use may be justified in
algorithms to sift through many models in order to select some that have predictive
performance worthy of more thorough evaluation, i.e., discovery research.
3.8 Recommendations
For evaluating a single risk prediction model we have the following recommenda-
tions:
(i) Assess the model for its calibration in the population of interest and if necessary
recalibrate the model.
(ii) Plot the case and control risk distributions, possibly providing a summary index
of distance between the distributions as a descriptive adjunct.
(iii) In collaboration with clinical and health policy colleagues, elicit a risk threshold
or several thresholds that could be used for making treatment decisions. Evaluate
the model in terms of corresponding case and control classification rates and in
terms of net benefit of using the model.
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4 Comparing Two Risk Models
In this section we consider the comparison of two risk models for their prediction
performance. In a nutshell we recommend that (i) each model be evaluated for its
calibration; (ii) plots of risk distributionsand net benefit be prepared for each model;
(iii) having chosen a clinically relevant risk threshold for treatment (or several) com-
pare the corresponding case and control categorized risk distributions for the two
models and (iv) compare the corresponding net benefits associated with the two
models. An illustrative example is provided in Section 4.1. This approach applies
when the two models are nested (where one model has predictors X and the other
has additional predictors Y ) and when the models are not nested. Several methods
have been proposed in recent years for the specific problem of comparing nested
models, notably risk reclassification methods. We describe those risk reclassifica-
tion methods in section 4.3. Finally, we provide a result concerning the equivalence
of null hypotheses about improvement in prediction performance gained by adding
Y to a set of baseline predictors X and the classic null hypothesis about Y as a risk
factor after controlling for X .
4.1 Example
event rate (0.1017)
0.0
0.2
0.4
0.6
0.8
1.0
Risk
0 20 40 60 80 100
Risk percentile
risk(X)
risk(X,Y)
Fig. 9 Event rates for subjects in each decile of modeled risk align well with the risk values for
subjects in each decile that are shown with predictiveness curves.
We compare the logistic models, risk(X) and risk(X ,Y ), fit to our illustrative
data, as described in Section 1.3. Predictiveness curves for the fitted models super-
imposed with observed event rates in each decile of fitted risk are shown in Figure
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Fig. 10 Plots showing high risk classification for cases (D) and controls (D¯) under the baseline
model (X) and the expandedmodel (X ,Y ). A comparison of standardized net benefit is also shown.
9. Both models are well calibrated. The risk distributions in cases and controls are
shown in the left panel of Figure 10 using 1−cumulative distribution functions.
That is, for each risk threshold r we show the proportions of cases and controls
above that threshold. We see that at all thresholds more cases and fewer controls
have risks above the threshold when using the model risk(X ,Y ) than with model
risk(X). Consequently the case and control risk distributions are more separated by
the model risk(X ,Y ) than by the model risk(X). The measures of separation, AUC,
MRD, and AARD, are presented in Table 2, and confirm that greater separation is
achieved with the model includingY as a predictor.
Table 3
risk(X) risk(X ,Y) Difference
AUC 0.884 0.920 0.036
MRD 0.322 0.416 0.094†
AARD 0.599 0.673 0.074
HRD(0.20) 0.652 0.735 0.084
HRD¯(0.20) 0.089 0.084 −0.005
sNB(0.20) 0.455 0.550 0.095
PNF 0.174 0.134 −0.040
†difference in MRDs is called the IDI [16]
The right hand side of Figure 10 shows that, regardless of which risk threshold
is employed for recommending treatment, the expected benefit is larger when Y is
included in the risk model. This is not surprising since the change in the net benefit
is a weighted sum of the increase in the value HRD(r) plus the decrease in the value
of HRD¯(r), both of which are positive.
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sNB(X ,Y )(r)−sNBX (r)= {HR
(X ,Y)
D (r)−HR
X
D(r)}+
(1−ρ)
ρ
r
(1− r)
{HRX
D¯
(r)−HR
(X ,Y )
D¯
(r)}
Suppose that subjects with risks above 20% are recommended for treatment be-
cause the net benefit of treatment to a (would-be) case is considered 4 times the net
cost of treatment to a (would be) control. The model that includes Y recommends
8.4% more cases and .5% fewer controls for treatment. Relative to a perfect predic-
tion model, the model with X only achieves 45.5% of maximum benefit while that
includingY as well as X achieves 55.0% of maximum benefit. That is, the standard-
ized net benefit or discounted true positive rate is improved by 9.5%.
We also consider performance when certain criteria are set by policy mak-
ers. Suppose that a treatment risk threshold will be employed that will guarantee
w = 70% of cases are treated. Using the model with X only will require treating
PNF(w) = 17.4% of the population (and correspondingly ROC−1(w) = 0.114 of
controls) since the largest risk threshold exceeded by 70% of cases is rXH(w)= 0.167.
On the other hand, a higher risk threshold r
(X ,Y)
H (w) = 0.231, can be employed
with the model risk(X ,Y) as the case risk distribution is higher. Consequently only
PNF(w) = 13.4% of the population (and only ROC−1(w) = 0.07 of controls) will
be treated if risk(X ,Y ) is used for assigning treatment.
In this example, better performance is achieved by includingY in the risk model
regardless of how performance is measured.
4.2 Risk Reclassification within Subpopulations Defined by risk(X)
In addition to determining whether or not use of the model risk(X ,Y ) is better than
use of risk(X) in the population as a whole, one might ask if the additional informa-
tion provided by knowledge of Y is useful in subsets of the population. Specifically,
one might consider subsets of the population determined to be at low (or high or
intermediate) risk according to risk(X) and evaluate use of the enhanced model
risk(X ,Y ) in that subpopulation. This is one motivation for constructing the risk
reclassification table illustrated in Table 4.
Table 4 shows risk reclassification tables for cases in the ‘Events’ panel of the
table and for controls in the ‘Nonevents’ panel of the table. In cardiovascular dis-
ease the tables are often constructed using 3 categories corresponding to the 3 treat-
ment recommendations. Here we focus on the most important reclassifications to
or from the high risk category that associated with cholesterol lowering treatment,
and ignore reclassification between the medium and low risk categories that are
less consequential. Table 5 summarizes the performance of the enhanced model
risk(X ,Y ) within each of the subpopulations determined to be at low (< 5%),
medium(5−20%) and high(> 20%) risk according to the baseline model, risk(X).
In the low risk population, where the event rate ρ = 1.89%, only 3.5% of those
cases are reclassified by Y to the high risk category and almost no controls 0.4% are
reclassified. The maximum possible benefit is to reclassify all cases (18.9 per 1000
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Table 4 Event and Nonevent Risk ReclassificationTables
Events
risk(X ,Y )
r(X) < 5% 5−20% ≥ 20% Total
≤ 5% 72 38 4 114 (11.2%)
5−20% 21 105 114 240 (23.6%)
≥ 20% 0 33 630 663 (65.2%)
Total 93 176 748 1017
(9.1%) (17.3%) (73.5%)
Nonevents
risk(X ,Y)
r(X) < 5% 5−20% ≥ 20% Total
≤ 5% 5486 399 21 5906 (65.8%)
5−20% 1015 990 272 2277 (25.3%)
≥ 20% 40 296 464 800 (8.9%)
Total 6541 1685 757 8983
(72.8%) (18.8%) (8.4%)
Table 5 Performance of r(X ,Y) within strata defined by r(X)
ρ(X) cases controls % of max benefit
Population Event Rate HRD(0.20) HRD¯(0.20) sNB(0.20)
low risk r(X) 1.89% 0.035 0.004 −1.7%
med risk r(X) 9.54% 0.475 0.119 19.3%
high risk r(X) 45.32% 0.950 0.580 25.4%
subjects) and no controls but the model reclassifies only 3.5% of the cases (0.66
cases per 1000 subjects). Consequently, the standardized net benefit of using the
model is negligible. (The negative value,−1.7%, must be due to sampling variability
as the net benefit cannot be negative if the model is correct.) It appears that use of Y
in the low risk population is not beneficial.
In the medium risk population, 47.5% of the cases are favorably reclassified to
the high risk group while only 11.9% of the controls are. The maximum possible
benefit is that achieved if all 95.4/1000 cases were moved to the high risk category
without moving any of the 904.6/1000 of the controls. With use of Y it appears that
sNB(0.2) = 19.3% of this maximum possible benefit is achieved. In other words
the benefit reached by measuring Y in the medium risk population is the same as
that achieved by a model that moved about 19/1000 cases to treatment with statins
without moving any controls into that high risk category.
In the high risk group, benefit can be obtained by moving controls down to a
lower risk category but at the possible cost of moving cases down. The reclassifica-
tion tables show however that with use of Y only 5% of the cases are moved down
while 42% of controls move down. The maximum benefit in a population of 1000
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subjects would be that achieved by moving none of the 453 cases but all of the 547
controls down. With use of Y , we are able to move 230 controls off treatment at the
expense of moving 23 cases off treatment. Is this a net benefit? Arguments similar
to those in Section 3.4 can be used to show the standardized net benefit of a rule that
denies treatment when the risk< rH in a population with prevalence ρ is
sNB(rH) = {1−HRD¯}−
ρ
1−ρ
1− rH
rH
{1−HRD(rH)}.
We calculate that sNB(rH) = 25.4% of maximum benefit is achieved with use of
Y in the population deemed at high risk according to risk(X). This is equivalent to
moving .254×547= 140 controls down without moving any cases in a set of 1000
subjects. This benefit seems substantial.
We find risk reclassification tables useful for evaluating an expanded model
risk(X ,Y ) within subpopulations defined by risk levels calculated according to the
baseline model risk(X), as illustrated above. One might also choose to plot risk
distributions and calculate other statistics for evaluating a risk model within each
subpopulation using techniques described in Section 3. However, analyses of risk
reclassification tables have been proposed for purposes beyond evaluation use of
risk(X ,Y )within subpopulations defined by risk(X). In particular, analyses that pur-
port to compare the two models in the entire population have been proposed. In the
next section we describe the two main approaches that have been proposed and point
out some fundamental weaknesses in them.
4.3 Risk Reclassification to Compare Two Models
4.3.1 The Cook and Ridker Analysis Method
Cook and Ridker [4] combine the event and nonevent reclassification tables in a
single table with the elements shown in Table 6.
Table 6 Risk reclassification tables showing numbers of subjects and event rates (%) in each cell.
risk(X ,Y )
r(X) ≤ 5% 5−20% > 20% Total
≤ 5% 5558 437 25 6020
1.30 8.71 16.00 1.89
5−20% 1036 1095 386 2517
2.03 9.59 29.53 9.54
> 20% 40 329 1094 1463
0.00 10.03 57.59 45.32
Total 6634 1861 1505 10,000
1.40 9.46 49.70 10.17
http://biostats.bepress.com/uwbiostat/paper384
Methods for Evaluating Prediction Performance of Biomarkers and Tests 27
They calculate the following entities that are explained below:
(i) the overall reclassification rate = RC
(ii) the percent correctly reclassified = RC-correct
(iii) the baseline model reclassification calibration statistic: RCCX and its p-value
(iv) the expanded model reclassification calibration statistic: RCC(X ,Y) and its p-value
The RC is the proportion of subjects in the off-diagonal cells of the table, 22.5%
in our example. This is simply a descriptive statistic that is not used to compare
models although a small value indicates that treatment recommendations will be
changed for few subjects by includingY as a risk predictor in addition to X .
The RC-correct is defined to be the proportion of subjects in off-diagonal cells
where the observed event rate is within the risk(X ,Y) category label and not within
the risk(X) category label. In our data RC-correct= 100%. If the RC-correct value
is large, this is taken as evidence that prediction performance with the model that
includes Y is better than prediction performance with the reduced model risk(X).
However, it has been shown that by definition, when models are well calibrated
in the standard sense, RC-correct≈ 100% in large samples. This follows because
for observations in an off-diagonal cell where risk(X) ∈ A and risk(X ,Y ) ∈ B the
expected event rate
P(D= 1|risk(X) ∈ A, risk(X ,Y ) ∈ B)
=E(D= 1|risk(X) ∈ A, risk(X ,Y) ∈ B)
=E(E(D = 1|X ,Y)|risk(X) ∈ A, risk(X ,Y ) ∈ B)
=E(risk(X ,Y )|risk(X) ∈ A, risk(X ,Y ) ∈ B).
This average risk is in the interval B because for all subjects in the off-diagonal
cell, risk(X ,Y ) ∈ B. Moreover, the average risk is not in the interval A because,
being an off-diagonal cell, the interval A lies outside of interval B. It follows that
for each off-diagonal cell, in large samples the event rate is in the interval defined
by the enhanced model. That is, we expect that RC-correct = 100%. Any deviation
from 100% that occurs must be due to sampling variability. There is no point in
calculating a statistic that is≈ 100% by definition and it cannot be used to compare
the performances of the two models.
The reclassification calibration statistics are:
RCCX =
K
∑
k=1
(p̂k−ave(risk(X))k)
2
ave(risk(X))k(1−ave(risk(X))k)/nk
and
RCC(X ,Y) =
K
∑
k=1
(p̂k−ave(risk(X ,Y ))k)
2
ave(risk(X ,Y ))k(1−ave(risk(X))k)/nk)
where the summation is over the K interior cells of the table with sample sizes
nk ≥ 20, ave(risk( ))k is the average of modeled risks for subjects in cell k and
p̂k is the observed event rate in that cell. Cook and Ridker refer the reclassification
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calibration statistics to chi-squared distributions with K−2 degrees of freedom for
calculating p-values.
The arguments above show that in large samples the observed event rates in off-
diagonal cells converge to ave(risk(X ,Y ))k but not to ave(risk(X))k . Therefore the
implicit null hypothesis for the statistic RCC(X ,Y) is satisfied. That is, the enhanced
model will not be rejected at a rate above the nominal significance level in large
samples. On the other hand the implicit null hypothesis for the baseline model will
be rejected in large samples assuming that Y is a risk factor that moves even a
small proportion of subjects to off-diagonal cells. In other words, if there are sub-
jects in off-diagonal cells, there is no point in performing the RCC (X ,Y) statistical
test since the result is predetermined in large samples. If there are no subjects in
off-diagonal cells the setting is degenerate and there is obviously no point in per-
forming the test either. We implemented the RCC tests on our illustrative data and
in agreement with our arguments above, the baseline model was rejected, p< .001,
while the enhanced model was not, p= 0.29.
In conclusion, we regard the risk-reclassification table proposed by Cook and
Ridker [4] as an interesting descriptive device. However, the analysis strategy based
on the table is not useful for comparing risk models.
4.3.2 The Net Reclassification Index
Pencina et al. [16, 17] introduced the Net Reclassification Index (NRI) as a mea-
sure to compare the prediction performance of nested risk models. The statistic is
calculated as the sum of two components, the NRI-event and NRI-nonevent. When
risk categories exist, the data are summarized in reclassification tables of the form
shown in Table 4 and the corresponding NRI statistics are
cat-NRI-event= P[riskc(X ,Y )> riskc(X)|D= 1]−P[riskc(X ,Y )< riskc(X)|D= 1]
cat-NRI-nonevent= P[riskc(X ,Y )< riskc(X)|D= 0]−P[riskc(X ,Y )> riskc(X)|D= 0]
cat-NRI= cat-NRI-event+ cat-NRI-nonevent
where riskc(X ,Y ) is the risk category in which the subject’s value for risk(X ,Y)
falls and riskc(X) is that in which his value of risk(X) falls. In words, cat-NRI-
event is the proportion of cases above the diagonal of the event reclassification table
minus the proportion below the diagonal. The counterpart, cat-NRI-nonevent is the
proportionof controls below the diagonal minus the proportion of controls above the
diagonal. Their sum, cat-NRI, takes values between 0 and 2. For our data with 3 risk-
categories, cat-NRI-event= 0.100, cat-NRI-nonevent=0.073 and cat-NRI=0.174.
The cat-NRI provides a descriptive summary of the reclassification tables. How-
ever, it does not seem particularly well suited to the purpose of comparing the pre-
diction performance of the models risk(X) and risk(X ,Y ). In general it does not
represent a comparison of the performance of the model risk(X ,Y) with the perfor-
mance of the model risk(X). To see this, consider that the performance of the model
risk(X) must be derived from the case and control distributions of risk(X). These
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distributions are contained in the vertical margins of the event and nonevent reclas-
sification tables, respectively. Similarly the performance of the model risk(X ,Y)
must be derived from the horizontal margins of the reclassification tables. However,
the cat-NRI statistic is a function that depends on the interior cells of the tables, not
just their margins. This is illustrated in Table 7 that shows an example where the
margins of the reclassification tables are equal but cat-NRI> 0.
Table 7 Example where cat-NRI> 0 but there is no performance improvement.
Events r(X ,Y)
low med high
low 10 10 0 20
r(X) med 5 20 10 35
high 5 5 35 45
20 35 45 100
Non-Events r(X ,Y)
low med high
low 500 100 0 600
med 100 200 0 300
high 0 0 100 100
600 300 100 900
That is, in Table 7, prediction performance for the model risk(X ,Y ) is the same as
that for the model risk(X) since the vertical and horizontal margins are equal. How-
ever, the cat-NRI statistic= (20−15)/100= 0.05> 0, indicating that performance
has improved.
Although the cat-NRI statisticwas originally proposed for use with 3 or more risk
categories, it is interesting to consider it in the simpler and more common setting
where only two risk categories exist that are separated at a treatment risk threshold
rH . Using the notation in Table 8, it is easy to see that with two categories
cat-NRI-event= b− c= b+d− (c+d) =HR
(X ,Y)
D (rH)−HR
X
D(rH)
cat-NRI-nonevent= f −g= f +h− (g+h) = HRX
D¯
(rH)−HR
(X ,Y)
D¯
(rH)
cat-NRI= {HR
(X ,Y)
D (rH)−HR
X
D(rH)}−{HR
(X ,Y )
D¯
(rH)−HR
X
D¯
(rH)}.
That is, cat-NRI-event is the increase in the proportionof cases classified as high risk
and cat-NRI-nonevent is the decrease in the proportion of controls classified as high
risk. The simple summation that is cat-NRI however, does not weight the relative
contributions appropriately unless rH = ρ . To see this, recall that the change in the
standardized net benefit does weight the contributions appropriately and is written
as
sNB(X ,Y )(rH)−sNB
X(rH)= {HR
(X ,Y)
D (rH)−HR
X
D(rH)}−
1−ρ
ρ
rH
(1− rH)
{HR
(X ,Y )
D¯
(rH)−HR
X
D¯
(rH)}.
Only when rH = ρ does cat-NRI correspond to the appropriately weighted combi-
nation, the change in sNB(rH). Interestingly a weighted version of the two-category
NRI statistic has recently been proposed to correspond with the form of change in
sNB(rH), by weighting cat-NRI-nonevent by
(1−ρ)
ρ
rH
(1−rH )
[17]. However, weighted
versions of the cat-NRI statistic have not been proposed to correspond with change
in standardized net benefit when more than two categories are involved.
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Table 8 Example where cat-NRI> 0 but there is no performance improvement.
Events
r(X ,Y )
low high
low a b
high c d
Non-Events
r(X ,Y)
low high
low e f
high g h
A continuous version of the NRI statistic has been proposed for use when no
clinically relevant risk categories exist:
cont-NRI-event= P(risk(X ,Y )> risk(X)|D= 1)−P(risk(X ,Y )< risk(X)|D= 1)
= 2P(risk(X ,Y )> risk(X)|D= 1)−1
cont-NRI-nonevent= P(risk(X ,Y )< risk(X)|D= 0)−P(risk(X ,Y )> risk(X)|D= 0)
= 1−2 P(risk(X ,Y )> risk(X)|D= 0)
cont-NRI= 2{P(risk(X ,Y) > risk(X)|D = 1)−P(risk(X ,Y ) > risk(X)|D= 0)}.
The statistic cont-NRI is also denoted by NRI(> 0). Again, since it is not a func-
tion of the marginal case and control risk distributions, cont-NRI does not seem
well suited to quantifying the improvement in prediction performance of the model
risk(X ,Y ) versus that of the model risk(X). It is not composed as a difference be-
tween an index of the performance of risk(X ,Y ) and an index of the performance
of risk(X). But it is an interesting easily understood descriptive statistic about the
joint distributions of (risk(X), risk(X ,Y)) based on the comparison of risk(X ,Y)
and risk(X) within individuals. In our data we calculate that for 69.4% of cases
their calculated risk increased with addition of Y and for 29.5% of controls their
risks increased with addition ofY . Consequently cont-NRI-event=0.388, cont-NRI-
nonevent= 0.411 and cont-NRI= 0.799.
4.4 Hypothesis Testing for Nested Models
When evaluating if a model that includes marker Y in addition to X improves perfor-
mance over the baseline model that includes X only, it is common practice to do sev-
eral hypothesis tests. One will typically test the hypothesisH10 : risk(X ,Y )= risk(X),
using, for example, likelihood techniques based on regression models. If H10 is re-
jected, one may test if the prediction performance of risk(X ,Y ) is equal to that of
risk(X) using one or more statistics, such as the difference in the AUCs or the IDI
statistic, which is the difference in MRDs, amongst others. The following result
indicates that the null hypotheses concerning many measures of performance im-
provement are identical to H10 : risk(X ,Y ) = risk(X).
The practical implication of this result is that if H10 is rejected, one can conclude
that the other hypotheses listed in Result 2 are also rejected. Testing any one of hy-
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potheses H20 −H
6
0 is equivalent to testing H
1
0 . We recommend using well standard
methods from regression modeling to test the hypothesis formulated as H10 . Corre-
sponding statistical techniques are well developed and they are often efficient. In
contrast techniques based on estimates of the performance measures in H20 −H
6
0 are
likely to be less efficient and have in some cases been shown to have bizarre dis-
tributions under the null hypothesis of no change in performance [13]. This is an
active area of research.
Result 2
The following conditions are equivalent
H10 : risk(X ,Y) = risk(X)
H20 : ROC
(X ,Y )( f ) = ROCX ( f ) ∀ f
H30 : AUC
(X ,Y) = AUCX
H40 : MRD
(X ,Y) =MRDX
H50 : AARD
(X ,Y) =AARDX
H60 : NRI(> 0) = 0
For a proof of Result 2 and additional related results see Pepe [22].
5 Concluding Remarks
We now recap some of the main points made in this chapter. First, a necessary
condition for a useful risk predictionmodel is that it be well-calibrated. Whereas the
scale of a marker used for classifying individuals according to disease status is not in
and of itself of interest, risks calculated using a prediction model are used to advise
a patient and to make medical decisions. The scale of the risk model predictions is
therefore a fundamental aspect of the model’s utility. Good calibration is essential.
The distributions of risk predicted by the model, for cases and for controls, are
the building blocks for evaluatingmodel performance. Summary measures are func-
tions of these distributions. A variety of summary measures have been described
here which rely on specification of a high risk threshold (or multiple risk thresh-
olds) for classifying subjects. Our preferred measures are the proportions of cases
and controls classified as high risk (or classified into each risk category) and the
standardized net benefit of using the model. Performance measures that do not rely
on risk thresholds can be useful for screening many models in order to select a
subset for further evaluation.
The choice of the risk threshold(s) should be based on an assessment of costs and
benefits associated with a high risk (or each risk category) designation. These costs
and benefits are also used in calculating the scaled net benefit of the model.
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When comparing models, our recommendation is to compare measures ofmarginal
performance. This is in contrast to basing comparisons on statistics that summarize
the cross-classification of the two models. The cross-classification is useful for de-
scriptive analysis but cannot be used as the basis for forming conclusions regarding
the relative performance of the two models.
When testing the incremental value of a new marker added to a risk model, stan-
dard likelihood methods should be used. Tests based on contrasts of performance
measures between the baseline and expanded risk models are testing the same null
hypothesis. These tests have, in some cases, been shown to poorly control the type-I
error rate and to be less powerful [13, 28, 22].
This chapter has focused on conceptual approaches to evaluation assuming a
very large sample size. In practice, where sample sizes are finite, all measures of
model performance should be accompanied by confidence intervals to characterize
the level of uncertainty. This practice is much more informative than reporting p-
values based on hypothesis tests; moreover in some instances as mentioned above,
tests based on model performance measures have poor properties. Bootstrapping is a
simple and flexible technique that can be used to construct confidence intervals. The
bootstrapping should reflect the actual data analysis that was performed; if the risk
model was fit using the data (versus using a separate dataset), the model should be
re-fit and performance estimated in each bootstrap sample. Bootstrapping is flexible
in that unique attributes of the original study design can be accommodated, such as
repeated measures or case-control sampling.
When a risk model is fit and evaluated using the same data, the apparent per-
formance will tend to be over-optimistic. This is particularly true if an intensive
model-selection procedure was employed. Standard approaches to dealing with this
problem include separating the data into “training” and “test” portions, and more
efficient methods such as cross-validation [8, 9]. The disadvantage of the latter ap-
proach is the requirement for a prespecified and automated model selection proce-
dure. If either approach is used, it should be reflected in the bootstrapping described
above. Specifically, in each bootstrap sample the complete model selection proce-
dure should be performed.
In many contexts there are covariates that need to be taken into account when pre-
dicting risk and evaluating risk model performance. We distinguish between covari-
ates (Z) that predict risk of bad outcome, eg age, and covariates that modify the per-
formance of a risk calculator (risk(X)), e.g., the laboratory in which the biomarker
X is assayed. Of course some coviarates, such as disease comorbidities, may have
both types of effects. For covariates that predict risk only, the approach is to simply
include these as predictors in the riskmodel, ie to modelP(D= 1|X ,Z)= risk(X ,Z).
To do this, the covariates Z are treated as additional markers and the methods de-
scribed in this chapter apply directly. On the other hand, covariates that modify the
distribution of risk(X) will have an impact on the performance of the model. Evalu-
ating how the performance of risk(X) varies with Z will generally require modeling
X as a function of Z and we refer the reader to Huang [11] for details. Covariates
that both predict risk and modify performance can be accommodated using the same
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methods where risk(X ,Z) is the risk calculator and the joint distribution of (X ,Z) is
modeled as a function of Z.
Our discussion of the choice of risk threshold(s) assumed implicitly that the cost
and benefit of being treated are constant across individuals, and in particular are
independent of the marker X . Markers that predict the benefit or cost of treatment
have greater potential net benefit [24, 29, 12]. However evaluating these markers
requires data from a randomized trial where the marker is measured at baseline, in
order to assess the cost and benefit of treatment as a function of X .
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